53 related articles for article (PubMed ID: 3448438)
1. [Efficacy and tolerance to pirozadil over a long term. Drug surveillance study. The Pirozadil Drug Surveillance Group].
Med Clin (Barc); 1987 Dec; 89(20):858-60. PubMed ID: 3448438
[No Abstract] [Full Text] [Related]
2. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
Tapounet R; Marti Ragué I
Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
[TBL] [Abstract][Full Text] [Related]
3. [A double blind study of the new hypolipidemic agent pirozadil (722-D) using patients with ischemic heart disease (author's transl)].
Cadierno Carpintero M; Emeterio Reig E; Soler Masana JM
Med Clin (Barc); 1982 May; 78(9):386-9. PubMed ID: 7047927
[No Abstract] [Full Text] [Related]
4. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
Honorato Pérez J; Azanza Perea JR
Rev Med Univ Navarra; 1982 Mar; 26(1):51-4. PubMed ID: 7111953
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
6. Application of simple lipid treatment goals in patients with atherosclerotic disease.
Svilaas A; Walsöe HK; Ose L
Nutr Metab Cardiovasc Dis; 2000 Apr; 10(2):71-8. PubMed ID: 10919171
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
9. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
10. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
11. HDL on the rise.
Alpert JS
Health News; 1999 Sep; 5(11):4. PubMed ID: 10513254
[No Abstract] [Full Text] [Related]
12. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
15. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with changes in serum total cholesterol levels over 7 years in middle-aged New Zealand men and women: a prospective study.
Metcalf PA; Scragg RK; Swinburn BA; Shaw LM
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):298-305. PubMed ID: 11887426
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidemia.
Duell PB; Illingworth DR
Curr Ther Endocrinol Metab; 1994; 5():475-84. PubMed ID: 7704776
[No Abstract] [Full Text] [Related]
18. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
[TBL] [Abstract][Full Text] [Related]
19. Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system.
Bryant SG; Fisher S; Kluge RM
J Clin Psychopharmacol; 1987 Apr; 7(2):78-82. PubMed ID: 3584525
[TBL] [Abstract][Full Text] [Related]
20. Evidence based hypolipidaemic drug treatment.
Mant A
Aust Fam Physician; 2000 Jan; 29(1):58-9. PubMed ID: 10721547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
